Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer

This is the authors' abstract. We don't add key points for this paper.

Considering the effectiveness of L-NMMA in decreasing tumor growth and enhancing survival rate in TNBC, we propose a targeted therapeutic clinical trial by re-purposing the pan-NOS inhibitor L-NMMA, which has been extensively investigated for cardiogenic shock as an anti-cancer therapeutic.